We are proud to announce that OASYS NOW has been awarded 3rd place in the 2025 KVK Innovatie Top 100, in the category Health & Nutrition. This annual ranking celebrates the most impactful and forward-thinking companies in the Netherlands, and we are honored to be recognized among such groundbreaking innovators.

The award highlights the transformative potential of our AI-driven clinical trial pre-screening solution: ELaiGIBLE.

Reinventing Clinical Trial Recruitment With ELaiGIBLE

Across Europe, clinical research faces a persistent bottleneck: identifying the right patients for the right studies. Manual pre-screening can take days to weeks, is error-prone, and places a heavy burden on clinicians already stretched for time.

ELaiGIBLE changes this reality.

Developed with privacy, security, and clinical impact at its core, ELaiGIBLE is Europe’s first fully AVG- and EU AI Act-compliant AI solution for real-time clinical trial pre-screening.

What makes ELaiGIBLE different?

• Real-time analysis of EHR data to instantly determine patient eligibility

• Understanding of medical free text, converting unstructured notes into structured eligibility logic

• Fully automated workflows, reducing weeks of manual screening to mere seconds

• Full compliance with AVG, ISO 27001, NEN 7510, and the EU AI Act

• Built-in pseudonymisation for maximum data protection

• Live deployment in research centers, with proven impact on accelerated inclusions

By enabling hospitals to find eligible patients faster — and with greater accuracy than ever before — ELaiGIBLE significantly accelerates clinical research timelines.

But its impact reaches far beyond operational efficiency.

Giving Patients Access to More Treatment Options

One of the most important benefits of ELaiGIBLE is its direct impact on patient care.

Every year, countless patients who could qualify for innovative clinical trials go unnoticed due to the limits of manual screening. ELaiGIBLE ensures these opportunities are no longer missed.

By analyzing patient profiles automatically and in real-time, the platform helps clinicians identify additional treatment options that patients may otherwise never have known existed — especially in therapeutic areas where options are limited.

This leads to:

• faster access to innovative therapies,

• more equitable participation in research,

• and improved outcomes for patients who need cutting-edge treatments most.

In other words: ELaiGIBLE is not just accelerating research — it’s expanding hope.

A Recognition That Resonates Across Healthcare

Winning 3rd place among the Netherlands’ most innovative startups validates the importance of privacy-first, AI-native innovation in healthcare.

We also want to extend a special congratulations to this year’s category winners:

🏆 Whispp – 1st place

🥈 Saturn Pelvic Health – 2nd place

Both companies are doing remarkable work to improve health outcomes, and we’re proud to be recognized alongside such impactful solutions.

Built for Europe’s Future of Responsible AI in Healthcare

At OASYS NOW, we believe that the future of clinical research can be:

• faster,

• more accurate,

• more secure,

• and more accessible — without ever compromising patient privacy.

ELaiGIBLE embodies this vision.

Our platform has already been adopted by hospitals and research centers across Europe, and we’re now expanding across disease areas, including CNS, cardiometabolic, and immune disorders. With an increasing number of clinical studies relying on our technology, we are committed to scaling our impact while upholding the highest standards of AI safety and regulatory compliance.

A Thank You to Our Community

This milestone would not have been possible without:

• the hospitals and research partners who trusted us early,

• the patients who inspire our mission every day,

• our dedicated team at OASYS NOW,

• and the KVK Innovatie Top 100 jury for recognizing the importance of safe, responsible, and high-impact healthcare innovation.

We’re grateful — and motivated — to keep pushing the boundaries of what’s possible.

The future of clinical research is privacy-first, AI-driven, and patient-centric. We’re just getting started. 🚀